US Edition
Assessing Benefit-Risk Profile of GA Therapies
Summary by modernretina.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Assessing Benefit-Risk Profile of GA Therapies
Panelists discuss how they present the modest efficacy of geographic atrophy (GA) therapies to patients by framing treatment as maintenance therapy that slows progression rather than providing improvement, using prior imaging to demonstrate disease advancement, acknowledging the inherent risk of developing wet age-related macular degeneration (AMD) while emphasizing that this preexisting risk is increased with complement inhibitor therapy, and o…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium